Kairos Pharma (KAPA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
29 Jun, 2026Opening remarks and agenda
Meeting called to order by CEO and Chairman John Yu, with executive officers introduced and agenda distributed to attendees.
Matters to be voted on included director elections, auditor ratification, reverse stock split, executive compensation, and equity plan amendments.
Shareholder proposals
Proposals included election of four directors, ratification of auditors, approval of a reverse stock split, advisory approval of executive compensation, and amendments to the equity incentive plan.
Motions to approve all proposals were made and seconded by stockholders Neil Bhowmick and Ramachandran Murali.
Overview of voting outcomes
All director nominees were elected to the board.
Auditor ratification, reverse stock split amendment, executive compensation, and equity incentive plan amendments (including a 5 million share increase and 10-year evergreen provision) were all approved.
Final voting results will be reported in a Form 8-K filing with the SEC within four business days.
Latest events from Kairos Pharma
- Net loss increased, cash declined, and continued operations depend on securing new funding.KAPA
Q2 2026 - Lead antibody ENV105 targets drug resistance in cancer, with key trial readouts expected soon.KAPA
Maxim Group’s 2024 Healthcare Virtual Summit - 2026 Annual Meeting set for June 29 with voting rights for shareholders as of May 18, 2026.KAPA
Proxy filing - Virtual meeting to vote on directors, auditor, reverse split, and expanded equity plan.KAPA
Proxy filing - Advancing drug resistance therapies with major 2026 clinical and partnership milestones ahead.KAPA
16th Annual LD Micro Invitational Conference - ENV105 and KROS 741 advance in trials to address cancer resistance, backed by strong funding.KAPA
Investor presentation - Q1 2026 net loss widened to $1.65M, cash at $3.68M, with new financing and manufacturing deals.KAPA
Q1 2026 - Stockholders will vote on director elections, a reverse split, auditor ratification, and equity plan changes.KAPA
Proxy filing - Net loss rose to $5.4M in 2025; cash of $4.5M may not fund operations for 12 months.KAPA
Q4 2025